Janssen says combination Phase III study for immunotherapy Darzalex for multiple myeloma shows significant PFS

pharmafile | June 6, 2016 | News story | Research and Development, Sales and Marketing ASCO, Drig Trial, Janssen, multiple myeloma 

Janssen said combination late stage trials for its immunotherapy drug to treat multiple myeloma showed 61% progression-free survival. 

The company said its Darzalex (daratumumab) also significantly increased the overall response rate in Phase III study. 

Jane Griffiths, company group chairman, Janssen Europe, Middle East and Africa, said: “The findings provide an important insight into the effect daratumumab can have in combination with established regimens, and illustrate the promise of this immunotherapy in earlier lines of treatment.” 

Darzalex was studied in combination with bortezomib (a proteasome inhibitor [PI]) and dexamethasone (a corticosteroid). 

Antonio Palumbo, myeloma unit chief, department of oncology, division of haematology, University of Torino, Italy, said: “We saw clinically meaningful improvements in progression-free survival and overall response rates with daratumumab when combined with standard of care. These compelling Phase III results demonstrate that a regimen built on daratumumab deepens clinical responses and help to underscore its potential for multiple myeloma patients who have been previously treated.” 

Anjali Shukla

Related Content


GSK shares results from phase 3 trial for Blenrep as multiple myeloma treatment

GSK has announced positive results from a planned interim efficacy analysis of the phase 3 …

GSK enters agreement for license for JNJ-3089 for development of bepirovirsen

GSK and Arrowhead Pharmaceuticals have announced that they have come to an agreement with Janssen …

Janssen and Sanofi enter agreement for potential vaccine programme

Janssen Pharmaceuticals, a Johnson & Johnson company, has announced a development and commercialisation agreement with …

Latest content